Invest in theFuture of Genomics
Join us in revolutionizing personalized medicine through AI-powered genetic analysis. A $217B+ market opportunity with exponential growth potential.
$217B+
Market Size
Global Precision Medicine Market by 2028
487%
Revenue Growth
Year-over-Year Growth Rate
127+
Global Reach
Countries across 6 continents
3.2M+
Tests Processed
Genetic tests completed annually
Compelling Growth Metrics
Strong fundamentals and market leadership position us for continued exponential growth
Market Size
Global genomics market projected by 2028
The precision medicine market is experiencing unprecedented growth, driven by advances in AI and declining sequencing costs.
Revenue Growth
Year-over-year revenue increase
Consistent triple-digit growth driven by expanding test portfolio and global market penetration.
Customer Retention
Healthcare provider retention rate
Industry-leading retention demonstrates the value and reliability of our genetic testing platform.
Partner Network
Healthcare facilities worldwide
Strategic partnerships with hospitals, clinics, and research institutions across 45+ countries.
72%
Gross Margin
+8%$125M
ARR
+156%8.5:1
LTV:CAC
+2.1135%
Net Revenue Retention
+15%Massive Addressable Market
The global precision medicine market is projected to reach $217.8 billion by 2028, with genomics testing representing $66.5B+ growing at 19.4% CAGR
Pharmacogenomics
Personalized medication optimization based on genetic profiles
Oncology Testing
Hereditary cancer risk assessment and early detection
Nutrigenomics
Diet and nutrition optimization through genetic insights
Carrier Screening
Reproductive health and family planning genetics
$66.5B+
Total Market
by 2028
Growth Timeline
From startup to market leader in just 6 years
Company Founded
Gene Matrix AI launched with a vision to democratize genetic testing through AI-powered analysis.
First Product Launch
Released GeneCore comprehensive health panel, achieving 10,000 tests in first quarter.
Series A Funding
Raised $25M to expand test portfolio and establish international laboratory network.
Global Expansion
Opened labs in Europe and Asia, partnered with 200+ healthcare facilities worldwide.
Series B & AI Platform
Secured $75M Series B, launched proprietary AI engine with 99.9% accuracy rate.
Market Leadership
Reached 2.5M tests processed, expanded to 45+ countries with 850+ partner facilities.
Series C & IPO Track
Preparing for Series C funding and potential IPO, targeting $500M valuation.
World-Class Team
Industry veterans with proven track records in genomics, AI, and scaling healthcare companies
Tarek Younis
Chief Executive Officer
Tarek Younis is the visionary founder and CEO of Gene Matrix AI, leading the company's mission to revolutionize healthcare through AI-powered genetic diagnostics. With over 15 years of experience in healthcare technology and biotechnology.
Tarek Younis
Chief Executive Officer
Dr. James Chen
Chief Scientific Officer
Lammy Shaheen
Executive Director of Business & Operations
Saso Poposki
President of European Operations
Dr. Michael Okonkwo
Chief Medical Officer
Dr. Amara Nkosi
Director of African Markets
Advisory Board
Dr. Eric Lander
Former Science Advisor to President
Broad Institute
Mary Meeker
General Partner
Bond Capital
Dr. Francis Collins
Former NIH Director
NIH
John Doerr
Chairman
Kleiner Perkins
Partner With Innovation
Submit your inquiry to join our investment community and be part of the genomics revolution
Email IR Team
investors@genematrixai.com
Call Us
+1 (888) 555-GENE
Schedule Meeting
Book a Call